FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2616932141> ?p ?o ?g. }

• W2616932141 endingPage "2383" @default.
• W2616932141 startingPage "2383" @default.
• W2616932141 abstract "Abstract Myelodysplastic syndromes (MDS) are clonal stem cell diseases of the bone marrow (BM) characterized by a dysfunction of hematopoiesis commonly resulting in cytopenias, dysplasia and an increased risk of acute myeloid leukemia (AML) development. In up to 90% of MDS cases acquired somatic mutations can be identified. Additionally, these aberrations constitute important markers for diagnosis and risk stratification. Currently, the use of BM aspirates is the gold standard for cytogenetic and molecular genetic analysis. However, frequent analyses of peripheral blood (PB) samples are of special interest for monitoring the natural course and therapy response in MDS since this might not be feasible with BM specimens due to ethical and other reasons. The aim of this study was to investigate whether the high sensitivity of targeted deep sequencing (TDS) allows reliable detection of somatic variants also from PB samples and whether the molecular profiles are comparable between these different sources of material. Additionally robustness, feasibility and comparability of the method were verified by inter-laboratory comparisons. This study included 31 patients from two centers, in Barcelona (Spain) and Göttingen (Germany) (12x RCMD, 4x RAEB-2, 4x sAML, 4x CMML-1, 2x MDS-RA, 1x MDS-U, 1x RAEB-1, 1x RCMD-SA, 1x RARS, 1x CCUS). For all patients, genomic DNA was extracted from concurrent mononuclear or total bone marrow cells (BMC), mononuclear peripheral blood cells (PBMC) and immunomagnetically (MACS) enriched circulating CD34+ cells (CD34+). Library preparation was performed using a custom hybridization-probe based panel (Nimblegen SeqCap EZ, Roche) including 83 myeloid-related genes (Barcelona) or the TruSight Myeloid Sequencing-Panel (Illumina) including 53 target genes (Göttingen). Sequencing was performed on MiSeq instruments. Reads were analyzed using local bioinformatic pipelines. Variants were filtered according to read depth (> 100x), population frequency (< 1%), their impact on protein integrity or function and evaluated by visualization on the Integrative Genome Viewer Software. Somatic origin of the variants was confirmed by sequencing of control samples from MACS enriched circulating T-lymphocytes (CD3+). Somatic mutations were discovered in 29 of the 31 analyzed patients. Overall we identified 76 aberrations in 22 genes (12x TET2, 7x SF3B1, 7x SRSF2, 5x EZH2, 5x ASXL1, 5x U2AF1, 5x RUNX1, 4x ZRSR2, 4x TP53, 3x NRAS, 3x STAG2, 2x DNMT3A, 2x IDH1, 2x BCOR, 2x KRAS, 2x PTPN11, 1x PDGFRB, 1x IKZF1, 1x IDH2, 1x ATRX, 1x CSNK1A1, 1x ETV6). Literally all variants were found in BMC (n=74) as well as in circulating CD34+ cells (n=72) and PBMC (n=73). The discordance between the three sample types was random (5x RCMD, 2x sAML, 1x MDS-RA, 1x RARS). However, for five variants the allele frequency (VAF) values, which correlate with the clone size of the malignant cell population, were below 5% in PBMC samples. Therefore these variants were likely to be overlooked in case only PBMC would have been tested. There was no significant difference (p=0.774) between the VAF values measured in BMC (average: 40.0%) and enriched CD34+ cells (average: 41.3%). In contrast VAF values of PBMC (average: 30.1%) deviate significantly from both, BMC (p=0.007) as well as circulating CD34+ cells (p=0.027) (Figure 1). Our findings indicate that TDS enables the adequate detection of somatic mutations from BM, circulating CD34+ cells and for the most part also in PBMC preparations. However, the malignant cell population seems to be less abundant in the PBMC fraction and therefore the detection and especially the quantification of clonal somatic variations is more challenging in this sample type. In the present study we demonstrate that enrichment of circulating CD34+ cells from PB can overcome this problem and provide data that are equivalent to the results obtained from the analysis of BMC, especially for follow up or minimal residual disease analyses. We conclude that enrichment of CD34+ cells from PB constitutes an appropriate alternative for the reliable detection and quantification of somatic aberrations in MDS patients. Usage of circulating CD34+ cells in routine diagnostic next generation sequencing applications would significantly reduce invasive clinical interventions and could therefore improve diagnostics and disease monitoring. Support: PI 11/02010, PI/14/00013, RD12/0036/0044, AR 14/34, R14/03, SGR225 Disclosures No relevant conflicts of interest to declare." @default.
• W2616932141 created "2017-06-05" @default.
• W2616932141 creator A5016773523 @default.
• W2616932141 creator A5017040834 @default.
• W2616932141 creator A5018807515 @default.
• W2616932141 creator A5025105332 @default.
• W2616932141 creator A5025663121 @default.
• W2616932141 creator A5025699919 @default.
• W2616932141 creator A5027149922 @default.
• W2616932141 creator A5033929940 @default.
• W2616932141 creator A5036867361 @default.
• W2616932141 creator A5046140085 @default.
• W2616932141 creator A5063948019 @default.
• W2616932141 creator A5067159029 @default.
• W2616932141 creator A5068609729 @default.
• W2616932141 creator A5080563231 @default.
• W2616932141 creator A5082287365 @default.
• W2616932141 creator A5087728922 @default.
• W2616932141 creator A5087964828 @default.
• W2616932141 creator A5089354375 @default.
• W2616932141 creator A5090544415 @default.
• W2616932141 date "2016-12-02" @default.
• W2616932141 modified "2023-10-16" @default.
• W2616932141 title "In MDS Targeted Deep Sequencing of CD34+ Blood Cells but Not Peripheral Blood Mononuclear Cells Give Results Which Are Representative for Bone Marrow" @default.
• W2616932141 doi "https://doi.org/10.1182/blood.v128.22.2383.2383" @default.
• W2616932141 hasPublicationYear "2016" @default.
• W2616932141 type Work @default.
• W2616932141 sameAs 2616932141 @default.
• W2616932141 citedByCount "0" @default.
• W2616932141 crossrefType "journal-article" @default.
• W2616932141 hasAuthorship W2616932141A5016773523 @default.
• W2616932141 hasAuthorship W2616932141A5017040834 @default.
• W2616932141 hasAuthorship W2616932141A5018807515 @default.
• W2616932141 hasAuthorship W2616932141A5025105332 @default.
• W2616932141 hasAuthorship W2616932141A5025663121 @default.
• W2616932141 hasAuthorship W2616932141A5025699919 @default.
• W2616932141 hasAuthorship W2616932141A5027149922 @default.
• W2616932141 hasAuthorship W2616932141A5033929940 @default.
• W2616932141 hasAuthorship W2616932141A5036867361 @default.
• W2616932141 hasAuthorship W2616932141A5046140085 @default.
• W2616932141 hasAuthorship W2616932141A5063948019 @default.
• W2616932141 hasAuthorship W2616932141A5067159029 @default.
• W2616932141 hasAuthorship W2616932141A5068609729 @default.
• W2616932141 hasAuthorship W2616932141A5080563231 @default.
• W2616932141 hasAuthorship W2616932141A5082287365 @default.
• W2616932141 hasAuthorship W2616932141A5087728922 @default.
• W2616932141 hasAuthorship W2616932141A5087964828 @default.
• W2616932141 hasAuthorship W2616932141A5089354375 @default.
• W2616932141 hasAuthorship W2616932141A5090544415 @default.
• W2616932141 hasConcept C10205521 @default.
• W2616932141 hasConcept C109159458 @default.
• W2616932141 hasConcept C126322002 @default.
• W2616932141 hasConcept C137061746 @default.
• W2616932141 hasConcept C143998085 @default.
• W2616932141 hasConcept C202751555 @default.
• W2616932141 hasConcept C203014093 @default.
• W2616932141 hasConcept C2778729363 @default.
• W2616932141 hasConcept C2779282312 @default.
• W2616932141 hasConcept C2780007613 @default.
• W2616932141 hasConcept C2780817109 @default.
• W2616932141 hasConcept C28328180 @default.
• W2616932141 hasConcept C502942594 @default.
• W2616932141 hasConcept C54355233 @default.
• W2616932141 hasConcept C71924100 @default.
• W2616932141 hasConcept C86803240 @default.
• W2616932141 hasConceptScore W2616932141C10205521 @default.
• W2616932141 hasConceptScore W2616932141C109159458 @default.
• W2616932141 hasConceptScore W2616932141C126322002 @default.
• W2616932141 hasConceptScore W2616932141C137061746 @default.
• W2616932141 hasConceptScore W2616932141C143998085 @default.
• W2616932141 hasConceptScore W2616932141C202751555 @default.
• W2616932141 hasConceptScore W2616932141C203014093 @default.
• W2616932141 hasConceptScore W2616932141C2778729363 @default.
• W2616932141 hasConceptScore W2616932141C2779282312 @default.
• W2616932141 hasConceptScore W2616932141C2780007613 @default.
• W2616932141 hasConceptScore W2616932141C2780817109 @default.
• W2616932141 hasConceptScore W2616932141C28328180 @default.
• W2616932141 hasConceptScore W2616932141C502942594 @default.
• W2616932141 hasConceptScore W2616932141C54355233 @default.
• W2616932141 hasConceptScore W2616932141C71924100 @default.
• W2616932141 hasConceptScore W2616932141C86803240 @default.
• W2616932141 hasIssue "22" @default.
• W2616932141 hasLocation W26169321411 @default.
• W2616932141 hasOpenAccess W2616932141 @default.
• W2616932141 hasPrimaryLocation W26169321411 @default.
• W2616932141 hasRelatedWork W1969778053 @default.
• W2616932141 hasRelatedWork W2141586724 @default.
• W2616932141 hasRelatedWork W2236712884 @default.
• W2616932141 hasRelatedWork W2377112355 @default.
• W2616932141 hasRelatedWork W2416649916 @default.
• W2616932141 hasRelatedWork W3032185147 @default.
• W2616932141 hasRelatedWork W4230359604 @default.
• W2616932141 hasRelatedWork W4233417895 @default.
• W2616932141 hasRelatedWork W4240949613 @default.
• W2616932141 hasRelatedWork W4243856164 @default.
• W2616932141 hasVolume "128" @default.
• W2616932141 isParatext "false" @default.
• W2616932141 isRetracted "false" @default.

• next